What’s more, MK2206 (an AKT inhibitor) and LY-2584702 (a p70S6K inhibitor) reduced the phosphorylation of mTOR in the in vitro kinase assays and in ESCC cells, respectively (Figures 4C,D; Supplementary Figure S1). Here, RPS6KB1 is linked to esophageal squamous cell carcinoma.